SEC Company Response from VACCINEX, INC. (VCNX) (CIK 0001205922) (VCNX) — Mar 9, 2020
VACCINEX, INC. (VCNX) (CIK 0001205922)
Date: March 9, 2020 · CIK: 0001205922 · Accession: 0001193125-20-067342
AI Filing Summary & Sentiment
File numbers found in text: 333-236417
Letter
CORRESP - Acceleration for File # 333-236417
Vaccinex, Inc.
1895 Mount Hope Avenue
Rochester, New York 14620
March 9,
VIA EDGAR
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re: Vaccinex, Inc.
Registration Statement on Form S-3 (File No. 333-236417)
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Vaccinex, Inc. hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-3, as amended (the “Registration Statement”), and declare the Registration Statement effective as of 5:00 p.m., Eastern Daylight Time, on March 11, 2020, or as soon thereafter as possible.
Please feel free to direct any questions or comments concerning this request to William Intner of Hogan Lovells US LLP at (410) 659-2778.
Very truly yours,
Vaccinex, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP - Acceleration for File # 333-236417 Vaccinex, Inc. 1895 Mount Hope Avenue Rochester, New York 14620 March 9, 2020 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Vaccinex, Inc. Registration Statement on Form S-3 (File No. 333-236417) Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Vaccinex, Inc. hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-3, as amended (the “Registration Statement”), and declare the Registration Statement effective as of 5:00 p.m., Eastern Daylight Time, on March 11, 2020, or as soon thereafter as possible. Please feel free to direct any questions or comments concerning this request to William Intner of Hogan Lovells US LLP at (410) 659-2778. Very truly yours, Vaccinex, Inc. /s/ Scott E. Royer By: Scott E. Royer Title: Chief Financial Officer